Search

everythinglearnresearchcommunity

for

Search:↓

Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.

A woman's total hair loss from hepatitis C treatment grew back after stopping the medication.

Some patients may experience temporary total hair loss from hepatitis C treatment with PEG-interferon and ribavirin.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

A woman developed white patches on her skin and curly hair after hepatitis C treatment, likely due to the medication interferon alpha.

The cause of Frontal fibrosing alopecia, a type of hair loss, is complex, likely involving immune responses and genetics, but is not fully understood.

ILC1-like cells may contribute to hair loss in alopecia areata.

Stress in hair follicle stem cells causes inflammation in a chronic skin condition through a specific immune response pathway.

Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.

As of 1994, treatments for liver cancer had not significantly improved patient survival.

Hair follicle stem cells reduced hair loss and inflammation in mice with a condition similar to human alopecia.

A new mouse model for vitiligo helps study immune responses and potential treatments.

New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.

Certain immune molecules and stress affect hair loss, and while genes play a role, more research is needed to fully understand and treat it.

A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.

Lichen planopilaris may be an autoimmune disease causing hair loss due to immune system issues in hair follicles.

Alopecia areata severity and treatment response are linked to specific cytokine levels.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Certain immune cells contribute to severe hair loss in chronic alopecia areata, with Th17 cells possibly having a bigger impact than cytotoxic T cells.

Different treatments for alopecia areata have unpredictable results and varying success rates.

The research developed methods to test drugs that could protect and restore hair follicle protection in a hair loss condition.

Lichen Planopilaris and Frontal Fibrosing Alopecia may help us understand hair follicle stem cell disorders and suggest new treatments.

The document concludes that treatment for cutaneous T-cell lymphoma should be customized to each patient's disease stage, balancing benefits and side effects, with no cure but many patients living long lives.

Teriflunomide effectively reduces relapses and disability in MS and has a manageable safety profile.

A specific DNA sequence caused hair loss in male mice by activating immune cells and increasing a certain immune signal.

DM and AA may share a common cause.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Anifrolumab significantly improved skin lesions and hair regrowth in severe discoid lupus.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Alopecia areata is caused by immune system attacks on hair follicles, often triggered by viral infections.